Exploration of Targeted Anti-tumor Therapy

Table 1.

Predicted pioneer TFs in ERα dependent BC

Pioneer factors	Molecular/cellular context	Pioneer activity	References
FOXA1	Mitotic biomarker in human hormone-dependent cancer progression	Chromatin decompaction through binding to mitotic chromatin and recruitment of nuclear receptors	[33, 34]
TLE1	Ubiquitous expression in the endometrium, and immunohistochemical biomarker in breast carcinogenesis and synovial sarcoma diagnosis	Multitasking transcriptional corepressor that associate with condensed chromatin by binding to the histone tails of nucleosomes	[44, 45]
PBX1	Specific biomarkers for the diagnosis and prognosis of BC, prostate cancer, and an evident therapeutic target	Translates epigenetic cues and mediates estrogen-induced ERα binding	[28, 46]
AP2γ	The determinant of helix-span-helix domain and its binding affinity to DNA as a dimer is based on the net basic charge, the functional discrepancy of HS-1 hypersensitivity in ER-dependent cancer	Capable of transactivating human ERα promoter in BC through high-affinity AP2 sites in the untranslated leader sequence	[47, 48]
GATA3	Associated with endodermal development	Binds to nucleosomal DNA and actively promote decompaction of chromatin, induce nucleosome eviction	[49]
GATA4	Functionally associated with endodermal development	Capable of binding to compacted chromatin and to open the local nucleosome-rich domains, even in the absence of ATP-dependent chromatin remodeling enzymes, cooperative activity between FOXA1 in chromatin binding	[50, 51]